CLAIMS

1. An antitumor agent comprising an antitumor component blended with hydroxyapatite.

2. The antitumor agent of claim 1, wherein the method of administering a hydroxyapatite-blended antitumor agent includes administration by injection and/or infusion, and/or oral administration.

3. The antitumor agent of claim 1 and claim 2, wherein the antitumor component is an alkylating agent, an antimetabolite, an antitumor antibiotic, a plant preparation, a hormone preparation, an immunotherapeutic agent, a platinum preparation, or an antitumor agent not classified as above.

4. The antitumor agent of claims 1 to 3, wherein the antitumor component is cyclophosphamide, fluorouracil, bleomycin hydrochloride, bleomycin, bleomycin sulfate, etoposide, vincristine sulfate, interferon-β, cisplatin, carboplatin, nedaplatin, mitomycin C, doxorubicin, nimustine hydrochloride, fluorouracil, carboquone, paclitaxel, melphalan, vinblastine sulfate, dacarbazine, ifosfamide, thiotepa, vinorelbine tartrate, vinorelbine, neocarzinostatin, tegafur, methotrexate, vindesine sulfate, goserelin acetate, sobuzoxane, tretinoin, estramustine sodium phosphate, toremifene citrate, flutamide, hydroxycarbamide, cytarabine ocfosfate, mercaptopurine, tamoxifen citrate, doxifluridine, busulphan, gefinitib, imatinib mesilate, oxaliplatin, UFT, carmofur, aceglatone, anastrozole, ubenimex, fadrozole hydrochloride hydrate, procarbazine hydrochloride, or bicalutamide.

5. The antitumor agent of claims 1 to 4, comprising hydroxyapatite with a maximum particle size of 1 μm or less.

6. The antitumor agent of claims 1 to 4, comprising hydroxyapatite with a maximum particle size of 0.1 μm or less.

7. The antitumor agent of claims 1 to 4, comprising hydroxyapatite with a maximum particle size of 5 μm or less, wherein the antitumor agent is for oral administration.

8. The antitumor agent of claims 1 to 4, comprising hydroxyapatite with a maximum particle size of 0.5 μm or less, wherein the antitumor agent is for oral administration.

9. The antitumor agent of claims 1 to 4, wherein the amount of hydroxyapatite blended is 0.1 to 1000% of the antitumor component.

10. The antitumor agent of claims 1 to 4, comprising pulverizing the mixture of antitumor component and hydroxyapatite.